3 completed, 1 active not recruiting. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Active not recruiting 1 |
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
Follow Stanley Jordan, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant Clazakizumab - Kidney Failure, Chronic, End-Stage Renal Disease | Phase 1 / Phase 2 | Active not recruiting | Stanley Jordan, MD | 20 | 2018-02-27 | 2025-03-24 |
| Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant Clazakizumab - Antibody-mediated Rejection, Kidney Transplant; Complications | Phase 1 / Phase 2 | Completed | Stanley Jordan, MD | 10 | 2018-02-21 | 2025-05-06 |
| Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation Rituxan - End Stage Renal Disease | Phase 1 / Phase 2 | Completed | Stanley Jordan, MD | 41 | 2013-09-01 | 2018-10-26 |
| Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection C1 Esterase Inhibitor, Placebos - Kidney Transplantation | Phase 1 / Phase 2 | Completed | Stanley Jordan, MD | 20 | 2011-08-01 | 2017-03-21 |
Kidney Failure, Chronic (2) · Rejection, Psychology (1)
clazakizumab (2) · Complement C1 Inhibitor Protein (1) · Rituximab (1)
United States (4)